Valuation: Impax Laboratories Inc

Market Cap 5.79B 5.01B 4.68B 4.29B 8.07B 551B 8.2B 54.9B 21.55B 276B 21.75B 21.28B 914B P/E 2026 *
40.3x
P/E 2027 * 20.5x
Enterprise Value 8.07B 6.98B 6.52B 5.98B 11.24B 768B 11.42B 76.45B 30.01B 385B 30.29B 29.63B 1,272B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 2.26x
Free-Float
47.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2019-07-31
Chief Executive Officer 54 2019-07-31
Director of Finance/CFO 58 2023-11-06
Director TitleAgeSince
Director/Board Member 59 2023-11-06
Director/Board Member 70 2023-11-06
Director/Board Member 52 2023-11-06
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 5.79B
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +0.98%+0.87%+35.03%+49.58% 402.31B
Weighted average by Cap. +1.12%+1.22%+48.34%+75.33%

Financials

2026 *2027 *
Net sales 3.14B 2.72B 2.54B 2.33B 4.38B 299B 4.45B 29.79B 11.69B 150B 11.8B 11.55B 496B 3.39B 2.93B 2.74B 2.51B 4.72B 322B 4.8B 32.11B 12.6B 162B 12.72B 12.44B 534B
Net income 149M 129M 120M 110M 207M 14.16B 211M 1.41B 554M 7.1B 559M 547M 23.47B 295M 255M 238M 218M 411M 28.05B 417M 2.79B 1.1B 14.06B 1.11B 1.08B 46.48B
Net Debt 2.27B 1.97B 1.84B 1.68B 3.17B 216B 3.22B 21.54B 8.46B 108B 8.54B 8.35B 358B 1.85B 1.6B 1.49B 1.37B 2.58B 176B 2.62B 17.52B 6.88B 88.17B 6.94B 6.79B 291B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-